These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 28144969)
21. Delivery of antisense oligonucleotides for splice-correction of androgen receptor pre-mRNA in castration-resistant prostate cancer models using cell-penetrating peptides. Luna Velez MV; Paulino da Silva Filho O; Verhaegh GW; van Hooij O; El Boujnouni N; Brock R; Schalken JA Prostate; 2022 May; 82(6):657-665. PubMed ID: 35098567 [TBL] [Abstract][Full Text] [Related]
22. Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer. Sowalsky AG; Figueiredo I; Lis RT; Coleman I; Gurel B; Bogdan D; Yuan W; Russo JW; Bright JR; Whitlock NC; Trostel SY; Ku AT; Patel RA; True LD; Welti J; Jimenez-Vacas JM; Rodrigues DN; Riisnaes R; Neeb A; Sprenger CT; Swain A; Wilkinson S; Karzai F; Dahut WL; Balk SP; Corey E; Nelson PS; Haffner MC; Plymate SR; de Bono JS; Sharp A Clin Cancer Res; 2022 Aug; 28(16):3509-3525. PubMed ID: 35695870 [TBL] [Abstract][Full Text] [Related]
23. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer. McGrath MJ; Binge LC; Sriratana A; Wang H; Robinson PA; Pook D; Fedele CG; Brown S; Dyson JM; Cottle DL; Cowling BS; Niranjan B; Risbridger GP; Mitchell CA Cancer Res; 2013 Aug; 73(16):5066-79. PubMed ID: 23801747 [TBL] [Abstract][Full Text] [Related]
24. Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in prostate cancer therapy. Liao Y; Liu Y; Xia X; Shao Z; Huang C; He J; Jiang L; Tang D; Liu J; Huang H Theranostics; 2020; 10(8):3366-3381. PubMed ID: 32206096 [No Abstract] [Full Text] [Related]
25. Branched Chain RNA In Situ Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer. Saylor PJ; Lee RJ; Arora KS; Deshpande V; Hu R; Olivier K; Meneely E; Rivera MN; Ting DT; Wu CL; Miyamoto DT Clin Cancer Res; 2017 Jan; 23(2):363-369. PubMed ID: 27440270 [TBL] [Abstract][Full Text] [Related]
26. Calpain and AR-V7: Two potential therapeutic targets to overcome acquired docetaxel resistance in castration-resistant prostate cancer cells. Liu L; Lou N; Li X; Xu G; Ruan H; Xiao W; Qiu B; Bao L; Yuan C; Huang X; Wang K; Cao Q; Chen K; Yang H; Zhang X Oncol Rep; 2017 Jun; 37(6):3651-3659. PubMed ID: 28498452 [TBL] [Abstract][Full Text] [Related]
29. Gene amplification of YB-1 in castration-resistant prostate cancer in association with aberrant androgen receptor expression. Shiota M; Sekino Y; Tsukahara S; Abe T; Kinoshita F; Imada K; Ueda S; Ushijima M; Nagakawa S; Matsumoto T; Kashiwagi E; Takeuchi A; Inokuchi J; Uchiumi T; Oda Y; Eto M Cancer Sci; 2021 Jan; 112(1):323-330. PubMed ID: 33064355 [TBL] [Abstract][Full Text] [Related]
31. Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer. Park SE; Kim HG; Kim DE; Jung YJ; Kim Y; Jeong SY; Choi EK; Hwang JJ; Kim CS Invest New Drugs; 2018 Apr; 36(2):195-205. PubMed ID: 29110173 [TBL] [Abstract][Full Text] [Related]
32. DBC1 promotes castration-resistant prostate cancer by positively regulating DNA binding and stability of AR-V7. Moon SJ; Jeong BC; Kim HJ; Lim JE; Kwon GY; Kim JH Oncogene; 2018 Mar; 37(10):1326-1339. PubMed ID: 29249800 [TBL] [Abstract][Full Text] [Related]
33. Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. Zhang X; Morrissey C; Sun S; Ketchandji M; Nelson PS; True LD; Vakar-Lopez F; Vessella RL; Plymate SR PLoS One; 2011; 6(11):e27970. PubMed ID: 22114732 [TBL] [Abstract][Full Text] [Related]
34. The Transmembrane Protein TM4SF3 Interacts With AR and AR-V7 and is Recruited to AR Target Genes. Khatiwada P; Rimal U; Han Z; Malla M; Zhou J; Shemshedini L Endocrinology; 2023 Mar; 164(5):. PubMed ID: 36951301 [TBL] [Abstract][Full Text] [Related]
35. Plasma extracellular vesicles as phenotypic biomarkers in prostate cancer patients. Joncas FH; Lucien F; Rouleau M; Morin F; Leong HS; Pouliot F; Fradet Y; Gilbert C; Toren P Prostate; 2019 Nov; 79(15):1767-1776. PubMed ID: 31475741 [TBL] [Abstract][Full Text] [Related]
36. Kato T; Kawakami K; Mizutani K; Ando T; Sakai Y; Sakurai K; Toyota S; Ehara H; Ito H; Ito M Cancer Genomics Proteomics; 2023; 20(5):456-468. PubMed ID: 37643783 [TBL] [Abstract][Full Text] [Related]
37. Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation. Thelen P; Heinrich E; Bremmer F; Trojan L; Strauss A Prostate; 2013 Nov; 73(15):1699-709. PubMed ID: 23868789 [TBL] [Abstract][Full Text] [Related]
39. Urine-based liquid biopsy: non-invasive and sensitive AR-V7 detection in urinary EVs from patients with prostate cancer. Woo HK; Park J; Ku JY; Lee CH; Sunkara V; Ha HK; Cho YK Lab Chip; 2018 Dec; 19(1):87-97. PubMed ID: 30500003 [TBL] [Abstract][Full Text] [Related]
40. Nucleoporin 62 and Ca(2+)/calmodulin dependent kinase kinase 2 regulate androgen receptor activity in castrate resistant prostate cancer cells. Karacosta LG; Kuroski LA; Hofmann WA; Azabdaftari G; Mastri M; Gocher AM; Dai S; Hoste AJ; Edelman AM Prostate; 2016 Feb; 76(3):294-306. PubMed ID: 26552607 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]